Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02396238 · ClinicalTrials.gov registry record · NA
Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)
A NA study, sponsored by Cytori Therapeutics.
- Completed
- Registry status
- NA
- Development phase
- 88
- Enrollment target
NCT02396238: Completed NA study, sponsored by Cytori Therapeutics.
NCT02396238 is a NA study that has completed, run by Cytori Therapeutics. The registered enrollment target is 88 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02396238, a NA study, has completed, sponsored by Cytori Therapeutics.
- COMPLETED
- Registry status
- NA
- Development phase
- 88 participants
- Enrollment target
Study Summary
The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.
Interventions
- OTHER Placebo
- DEVICE Celution Device
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 88 participants |
| Start Date | 2015-05-15 |
| Est. Completion | 2018-05-22 |
| Phase | NA |
What the finished NCT02396238 record still lists
NCT02396238 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 88 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (94% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02396238 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02396238 about?
NCT02396238 is a clinical study titled "Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)". The primary objective of this study is to assess the safety and efficacy of the Celution Device in the processing of an autologous graft consisting of adipose derived regenerative cells (ADRCs) in the treatment of hand dysfunction due to scleroderma.
What is the current status of trial NCT02396238?
This trial is currently completed. It is a NA study. The enrollment target is 88 participants. The study started on 2015-05-15. Estimated completion is 2018-05-22.
What interventions are being tested in trial NCT02396238?
The interventions under investigation include: Placebo (OTHER), Celution Device (DEVICE).
Who is sponsoring clinical trial NCT02396238?
This trial is sponsored by Cytori Therapeutics, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02396238's enrollment target sits among peer trials
88 972nd of 2000 higher than 1,027 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03843463 · 88 participants · Phase 2
Escitalopram and Language Intervention for Subacute Aphasia
- NCT04066348 · 88 participants · Phase 2
TNF-α Treatment of Blast-Induced Tinnitus
- NCT04331704 · 88 participants · Phase 4
ANCHORS Alcohol & Sexual Health Study: UH3 Project
- NCT04536103 · 88 participants
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI